Developing a new dry powder aerosol treatment for lung issues in patients with respiratory distress
Official title: Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support
Funded at Virginia Commonwealth University · NIH-10863857 · Data updated 2026-11-12
This study is working on a new way to help people with serious breathing problems, like low oxygen levels or acute respiratory distress syndrome, by creating a dry powder that can be easily inhaled instead of using liquid treatments that can be harder to give.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $733,241 |
| NIH project number | 5R01HL164508-02 |
| Project ID | NIH-10863857 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults and children experiencing hypoxemia or ARDS due to direct lung injury.
✕Less likely to help
Patients with chronic respiratory conditions or those who do not experience acute respiratory distress may not benefit from this research.
What this research studies
This research focuses on creating a synthetic lung surfactant in dry powder form that can be delivered as an aerosol to patients suffering from hypoxemia or acute respiratory distress syndrome (ARDS). The approach aims to improve the delivery method compared to traditional liquid surfactant therapies, which often require invasive procedures and large volumes of liquid. By optimizing aerosol delivery strategies for various ventilation support methods, the research seeks to provide a safer and more effective treatment option for patients experiencing severe lung injury. The study will involve preclinical development to ensure the product is efficient and safe for use in clinical settings.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and less invasive treatment for patients with severe respiratory distress, potentially improving their recovery outcomes.
How similar studies have gone: While traditional surfactant therapies have faced challenges, this novel approach using dry powder aerosol delivery is relatively untested, presenting an opportunity for breakthrough advancements.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Longest, P. Worth — Virginia Commonwealth University
- Study coordinator: Longest, P. Worth
Related research
Other NIH-funded projects on the same topics.
-
Dry powder lung surfactant aerosol for people with low oxygen or ARDS on breathing support
This project is creating a dry powder lung surfactant you could inhale to help adults with low oxygen or ARDS who are on oxygen, noninvasive breathing support, or ventilators.
-
Developing a new dry powder aerosol to help patients with severe breathing problems
This study is testing a new dry powder treatment that can be turned into a mist to help people with breathing problems like hypoxemia or ARDS, and it aims to see if this treatment can reduce lung inflammation and work even better when combined with another medicine.
-
Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data
This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.
-
Resilience endotypes and early ARDS detection using biomarkers and AI
A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.
-
PAR1’s role in lung lymphatics and a new therapy approach for ARDS
This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.
-
Dead space and inhaled nitric oxide in pediatric ARDS
This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.